#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM
#OncoAlert #AACR20 Dose escalation of TAK-788 (mobocertinib) established MTD of 160mg qday. DLTs were 1 case each of grade 3 diarrhea, grade 3 mucositis, grade 3 pneumonitis, and grade 5 (fatal) pneumonitis. Study then enrolled into 7 different baskets to explore efficacy. #LCSM
#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM
#OncoAlert #AACR20 TAK-788 safety: At 160mg qd, G3+ AE in 40%, 25% dose reduction, 50% interruption. G3+ diarrhea 18%. Given the history of drugs here, does dose intensity correlate with DOR? I'm interested in G2 toxicities, which are very relevant here. Any QOL data? #LCSM
Encouraging data with TAK-788 (mobocertinib) in EGFR exon 20. The EXCLAIM expansion cohort of 91 patients already fully accrued. Also awaiting data from randomized EXCLAIM-2 randomized trial versus chemotherapy in 1L setting.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.